William A Richey, MD Radiology - Diagnostic Radiology Medicare: Not Enrolled in Medicare Practice Location: 3260 Hospital Dr, Juneau, AK 99801 Phone: 907-796-8631 Fax: 907-796-8455 |
Gordon T Blair, MD Radiology - Diagnostic Ultrasound Medicare: Not Enrolled in Medicare Practice Location: 3260 Hospital Dr, Juneau, AK 99801 Phone: 907-796-8631 Fax: 907-796-8455 |
Steven T Strickler, DO Radiology - Diagnostic Radiology Medicare: Accepting Medicare Assignments Practice Location: 3260 Hospital Dr, Juneau, AK 99801 Phone: 907-796-8900 |
Dr. Eugene Hsu Huang, M.D. Radiology - Radiation Oncology Medicare: Accepting Medicare Assignments Practice Location: 1701 Salmon Creek Lane, Juneau, AK 99801 Phone: 907-586-5762 Fax: 907-586-5777 |
News Archive
Thanks to the "flightless" molecule, the spread of cancer from one tissue to another may one day be grounded. In a new report published in the August 2012 print issue of The FASEB Journal, laboratory experiments show that "flightless" (named after its effects on fruit flies) increases the "stickiness" that causes cells, including cancer cells, to attach to underlying tissue, which in turn, slows their movement throughout the body.
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design and planned analysis of a Phase 3 clinical trial for the assessment of myocardial perfusion using Positron Emission Tomography (PET) imaging of flurpiridaz F-18 in patients with suspected or known coronary artery disease (CAD).
"Think your whole family is covered by your company health plan? Get ready to prove they're actually your kin." Under the new health overhaul law, starting next year "employers will have to provide coverage for dependents of employees [until] age 26. That will further inflate coverage costs for companies at a time when employers are already bracing for a 9% jump in their health care plan expenditures in 2011."
Exelixis, Inc. today announced it has initiated METEOR, a phase 3 pivotal trial comparing cabozantinib to everolimus in patients with metastatic renal cell carcinoma who have experienced disease progression following treatment with at least one prior VEGFR tyrosine kinase inhibitor.
A University of Illinois at Chicago researcher is the recipient of a $240,000 research grant to further explore the causes of myasthenia gravis, a neurologic disease affecting muscles.
› Verified 2 days ago